−4.6%
since Oct 2
The idea
I believe medicine by 2045 will look unrecognizable: diseases edited at the genetic root, drugs designed by AI, cancers caught at stage one. About a quarter of this take sits in established tools and equipment makers who get paid no matter which cure wins, with the rest spread across gene editing, early detection, new surgical and chronic care, and AI drug discovery, plus a small cash buffer. I avoid single-name concentration and hold for years, revisiting only if one of these fields stops advancing or a company's science clearly falls behind.
What it owns
- Gene editing and genetic medicine attack disease at the root instead of treating symptoms, with companies proving the approach works at scale and profit. · Vertex PharmaceuticalsIt already sells actual genetic cures at a profit, proof that the diseases-edited-at-the-root future pays if its pipeline keeps turning science into approved drugs., Alnylam PharmaceuticalsIt silences disease-causing genes with RNA and already makes money doing it, proving genetic medicine works at profit if sales of approved drugs keep growing., CRISPR TherapeuticsIt got the first CRISPR-based therapy approved, the most direct proof that the edited-at-the-genetic-root future is arriving., Regeneron PharmaceuticalsIt builds drugs from human genetic data at large, profitable scale, providing ballast inside the genetic-medicine bet if its approach keeps producing approved medicines., Beam TherapeuticsIt changes single DNA letters without cutting the strand, the next generation of editing technology, if clinical trials show the precision advantage is real., Intellia TherapeuticsIt edits genes inside the patient's body rather than in a lab dish, the harder and bigger version of the cure-at-the-root idea, if its trials keep reading well.26%
- Established equipment and lab suppliers get paid regardless of which cure or technology wins, as long as biotech research spending keeps growing. · Thermo Fisher ScientificIt sells the lab equipment and supplies every drug maker needs, so it gets paid whether gene editing, AI design, or something else wins., DanaherIt makes the gear that manufactures biologic drugs, the foundational tools needed as more genetic medicines move from lab to production., IlluminaIts sequencers are the standard way to read DNA, and reading the genome is step one for editing it, screening early, or feeding AI models, if sequencing volume grows., Agilent TechnologiesIts instruments measure and test what labs are building, an established tool paid regardless of which cure wins, as long as drug development volume keeps rising., West Pharmaceutical ServicesIt makes the vials, stoppers and delivery components that injectable drugs ship in, and most genetic medicines are injectables that will need these parts as volume grows.25%
- Blood tests that catch cancer at stage one change survival odds more than any new drug, if insurance coverage and test adoption keep growing. · Guardant HealthIt finds cancer from a blood draw, the core of catching cancers at stage one instead of stage four, if liquid biopsy keeps winning coverage and volume grows., NateraIts blood tests catch cancer coming back before scans can see it, early detection applied after treatment, if doctors keep adopting recurrence testing as standard care., GRAILIt screens healthy people for dozens of cancers with one blood test, the fullest version of the stage-one-not-stage-four bet, if its accuracy holds and insurance coverage follows.16%
- Robotic surgery and continuous glucose monitoring are already changing how care is delivered, and automation is spreading beyond early adopters. · Intuitive SurgicalIt dominates robotic surgery, the bet that how procedures get done changes as much as the drugs do, as long as surgeons keep shifting cases to its robots., DexComIt replaced finger pricks with a sensor that reads glucose around the clock, chronic care done a new way, if sensor adoption keeps spreading beyond insulin users., InsuletIts pump doses insulin automatically, closing the loop that continuous glucose monitoring opened, if automated insulin delivery keeps taking share from injections.13%
- Software that designs drugs could collapse the decade-long, billion-dollar path to a new medicine, if the candidate molecules advance in the clinic. · Tempus AIIt turns real patient records into the data AI drug discovery runs on, the fuel side of drugs designed by algorithm instead of tested by hand., SchrodingerIt designs drug molecules with physics simulations before anyone touches a test tube, drugs designed instead of discovered by trial and error, if its software revenue grows., Recursion PharmaceuticalsIt runs automated labs that let AI test drug ideas at industrial speed, the most direct version of the AI-designed-drugs bet, if its AI-found candidates advance in the clinic.12%
- Cash8%